Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors

Published on 04 Jun 2025
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Asciminib 20 mg and 40 mg tablets as monotherapy for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase whose disease is resistant and/or who are intolerant to two or more tyrosine kinase inhibitors.

Asciminib is not recommended for patients with T315I mutation.

Funding status

Asciminib 20 mg and 40 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.

MAF assistance does not apply to asciminib 100 mg tablet.

Clinical indication, subsidy class and MediShield Life claim limit for asciminib are provided in the Annex.

Guidance_Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors (Updated 6 Feb 2026)

PES_Asciminib for previously treated Philadelphia chromosome-positive chronic myeloid leukaemia (Updated 6 Feb 2026)